Compare Ascendis Pharma A/S (ASND) vs Flux Power Holdings Inc (FLUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Flux Power Holdings Inc — how do they compare? Ascendis Pharma A/S trades at $247 (market cap $16.71B), while Flux Power Holdings Inc trades at $0.59 (market cap $12.18M). The key difference: Ascendis Pharma A/S is far larger — about 1371.9× Flux Power Holdings Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ASND | FLUX | |
|---|---|---|
Market Cap | $16.71B | $12.18M |
Sector | Health | Utilities |
52-Week High | $277.18 | $6.66 |
52-Week Low | $189.74 | $0.51 |
Enterprise Value | $17.08B | $18.35M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
FLUX trades at $0.5702, up 8.82% today, but technical indicators signal a bearish trend with moving averages and ADX showing sell signals. The company reported mixed quarterly results, missing EPS estimates in Q3 2025 and Q1 2026 while beating in Q4 2025. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 6 buy ratings. Recent developments include the upcoming Q4 2026 earnings call and the launch of SkyEMS 3.0 with AI-powered fleet insights.
FLUX presents a high-risk opportunity with strong analyst support but fundamental challenges. The bullish sentiment from Wall Street contrasts with persistent losses and negative ROE/ROA. Key catalysts include execution on new product launches and path to profitability, while risks involve sustained cash burn and competitive pressure in clean energy storage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →
